CAS: 863971-53-3; Fmoc-Val-Cit-Pab-Pnp
该化合物是属于Peptide衍生物类别的化学化合物,专门设计用于peptide合成和药物开发."Fmoc"(9-氟甲基乙基碳基)组是氨基功能的保护组,允许合成过程中有选择的反应."Val"表示存在valine,一种必不可少的氨基酸,而"Cit"则指以其在各种生物过程中的作用而著称的柑橘."PAB"(p-aminobenzyl) 分子通常包括"PAB"(p-minobenzyl) 分子,因为它有能力促进与其他分子的融合或连接,加强化合物在生物合成应用中的效用.最后,"PNP"(可能指特定的功能组或协会)可能表明与治疗环境相关的其他特性或功能.
- 英文名称Fmoc-Val-Cit-Pab-Pnp
- 中文名称N-[(9H-氟代-9-甲氧基)羰基]-L-戊基-N5-(氨基羰基)-N-[4-[[[(4-硝基苯氧基)羰基]氧]甲基]苯基]-L-鸟氨酸酰胺
- IUPAC名称(9H-fluoren-9-yl)methyl ((S)-3-methyl-1-(((S)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate
- CAS编号863971-53-3
- MFCD编号:MFCD22200278
- EINECS号:813-100-1
- 分子式:C40H42N6O10分子量:766.8
- 产品CID: 1865398
- 产品分类有机原料→分子砌块→芳环类化合物→苯类化合物
- 相似结构搜索
- InChIKey: USMYACISHVPTHK-PXLJZGITSA-N
- RFBGUFDKKIFDDF-PXLJZGITSA-N
- 计算化学: 氢键受体数10.0氢键供体数5.0可旋转键数16.0
物理性质
MSDS等安全信息
欧盟法规
C&L通报合成工艺路线路线简述
- 合成目标产物 Fmoc-Val-Cit-Pab-Pnp 主要起始原料 Bis(4-Nitrophenyl) Carbonate And Fmoc-Val-Cit-Pab
- 159858-07-8 = 863971-53-3
反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol,Dimethylformamide; 5 H,Rt2.1 Solvents: Dichloromethane,Dimethylacetamide; 0 °C; 0 °C -> Rt; 2 H,Rt; 2 H,Rt3.1 Solvents: Dimethylformamide,Dichloromethane; Rt3.2 Reagents: Diisopropylethylamine Solvents: Dichloromethane; Rt; 18 H,Rt
标题:Linker Architectures As Steric Auxiliaries For Altering Enzyme-Mediated Payload Release From Bioconjugates
作者:Giese,Matthew; Et Al
参考文献:Bioconjugate Chemistry 日期:2021 卷标:32(10) 页码:2257-2267]
82911-69-1 + 159857-79-1 = 863971-53-3
反应条件:1.1 Solvents: Dichloromethane,Dimethylacetamide; 0 °C; 0 °C -> Rt; 2 H,Rt; 2 H,Rt2.1 Solvents: Dimethylformamide,Dichloromethane; Rt2.2 Reagents: Diisopropylethylamine Solvents: Dichloromethane; Rt; 18 H,Rt
标题:Linker Architectures As Steric Auxiliaries For Altering Enzyme-Mediated Payload Release From Bioconjugates
作者:Giese,Matthew; Et Al
参考文献:Bioconjugate Chemistry 日期:2021 卷标:32(10) 页码:2257-2267]
623-04-1 + 159858-06-7 = 863971-53-3
反应条件:1.1 Reagents: 2-Ethoxy-1-(Ethoxycarbonyl)-1,2-Dihydroquinoline Solvents: Isopropanol,Dichloromethane; 72 H,22 °C2.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol,Dimethylformamide; 5 H,Rt3.1 Solvents: Dichloromethane,Dimethylacetamide; 0 °C; 0 °C -> Rt; 2 H,Rt; 2 H,Rt4.1 Solvents: Dimethylformamide,Dichloromethane; Rt4.2 Reagents: Diisopropylethylamine Solvents: Dichloromethane; Rt; 18 H,Rt
标题:Linker Architectures As Steric Auxiliaries For Altering Enzyme-Mediated Payload Release From Bioconjugates
作者:Giese,Matthew; Et Al
参考文献:Bioconjugate Chemistry 日期:2021 卷标:32(10) 页码:2257-2267]
372-75-8 + 2813235-40-2 = 863971-53-3
反应条件:1.1 Reagents: Sodium Bicarbonate Solvents: Tetrahydrofuran,Water; Rt -> 35 °C1.2 Solvents: Tetrahydrofuran; 35 °C; 24 H,35 °C1.3 Reagents: Hydrochloric Acid Solvents: Water; Ph 32.1 Reagents: 2-Ethoxy-1-(Ethoxycarbonyl)-1,2-Dihydroquinoline Solvents: Isopropanol,Dichloromethane; 72 H,22 °C3.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol,Dimethylformamide; 5 H,Rt4.1 Solvents: Dichloromethane,Dimethylacetamide; 0 °C; 0 °C -> Rt; 2 H,Rt; 2 H,Rt5.1 Solvents: Dimethylformamide,Dichloromethane; Rt5.2 Reagents: Diisopropylethylamine Solvents: Dichloromethane; Rt; 18 H,Rt
标题:Linker Architectures As Steric Auxiliaries For Altering Enzyme-Mediated Payload Release From Bioconjugates
作者:Giese,Matthew; Et Al
参考文献:Bioconjugate Chemistry 日期:2021 卷标:32(10) 页码:2257-2267]
769-39-1 + 1149-26-4 = 863971-53-3
反应条件:1.1 Reagents: Dicyclohexylcarbodiimide Solvents: Tetrahydrofuran; Rt; Overnight,Rt2.1 Reagents: Sodium Bicarbonate Solvents: Tetrahydrofuran,Water; Rt -> 35 °C2.2 Solvents: Tetrahydrofuran; 35 °C; 24 H,35 °C2.3 Reagents: Hydrochloric Acid Solvents: Water; Ph 33.1 Reagents: 2-Ethoxy-1-(Ethoxycarbonyl)-1,2-Dihydroquinoline Solvents: Isopropanol,Dichloromethane; 72 H,22 °C4.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol,Dimethylformamide; 5 H,Rt5.1 Solvents: Dichloromethane,Dimethylacetamide; 0 °C; 0 °C -> Rt; 2 H,Rt; 2 H,Rt6.1 Solvents: Dimethylformamide,Dichloromethane; Rt6.2 Reagents: Diisopropylethylamine Solvents: Dichloromethane; Rt; 18 H,Rt
标题:Linker Architectures As Steric Auxiliaries For Altering Enzyme-Mediated Payload Release From Bioconjugates
作者:Giese,Matthew; Et Al
参考文献:Bioconjugate Chemistry 日期:2021 卷标:32(10) 页码:2257-2267
专利信息
专利号:WO-2024186075-A1
优先权日:2023-03-03
标题 :Synthesis method of antibody-drug conjugates using proximity effect-based site-selective antibody labeling
发明人：LEE HYUN SOO; KIM SOOIN; KWEON YONGSEOK
权利人:UNIV SOGANG RES & BUSINESS DEVELOPMENT FOUND; RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIV
摘要:The present invention relates to a method for the synthesis of an antibody-drug conjugate using proximity effect-based site-selective antibody labeling. Provided according to the present invention may be a method for the synthesis of an antibody-drug conjugate by site-selectively introducing a drug into an antibody using a pyridinium oxime derivative (labeling mediator protein) introduced into a binding protein containing a non-standard amino acid.
专利号:CN-117624284-B
优先权日:2023-11-29
标 题:Liquid phase synthesis method of linker and synthesis product thereof
专利号:EP-3033346-A1
优先权日:2013-08-14
标 题:Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
专利号:US-2022259202-A1
优先权日:2019-06-17
标题:1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
发明人：MEIMETIS LABROS
权利人:SUTRO BIOPHARMA INC
摘要:1-(4-(aminomethyl)benzyl)-2-butyl-2H-pyrazolo[3,4-c]quinolin-4-amine derivatives thereof and related compounds of formula (I) as toll-like receptor (TLR) 7/8 agonists for cancer therapy. Linker payload compounds thereof, and antibody conjugates thereof for cancer diagnosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 145 to 156; examples 1 to 3; biological examples 1 to 6; tables 1 and 2).
专利号:AU-2019204034-A1
优先权日:2013-08-14
标 题 :Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
专利号:AU-2014306592-B2
优先权日:2013-08-14
标题 :Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Sano K, Nakajima T, Miyazaki K, Ohuchi Y, Ikegami T, Choyke PL, Kobayashi H. Short PEG-linkers improve the performance of targeted, activatable monoclonal antibody-indocyanine green optical imaging probes. Bioconjug Chem. 2013 May 15;24(5):811-6. doi: 10.1021/bc400050k. Epub 2013 May 3.
2: Harrison E, Coulter JA, Dixon D. Gold nanoparticle surface functionalization: mixed monolayer versus hetero bifunctional peg linker. Nanomedicine (Lond). 2016 Apr;11(7):851-65. Review. pii: E1190. doi: 10.3390/molecules22071190.
4: Tuma R, Russell M, Rosendahl M, Thomas GJ Jr. Solution conformation of the extracellular domain of the human tumor necrosis factor receptor probed by Raman and UV-resonance Raman spectroscopy: structural effects of an engineered PEG linker. Biochemistry. 1995 Nov 21;34(46):15150-6. doi:10.1016/j.jconrel.2016.02.017. Epub 2016 Feb 8.
合成参考文献
摘要:Stephan K, Bischoff KO, Geigenmüller L, Diesch J, Meesmann W. [Effect of a new beta-sympatholytic agent for ICI 66 082 on hemodynamics and cardiac contraction without and with experimental coronary occlusion]. Verh Dtsch Ges Inn Med. 1975;81():1637–41.
📝 需求与反馈
尽可能描述清楚需求与问题信息
